Literature DB >> 9690696

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.

A L Nordström1, L Farde.   

Abstract

Previous studies of the relationship between plasma prolactin and clinical effects in patients treated with antipsychotic drugs have yielded inconsistent results. A possible explanation may be that most studies have not included subtherapeutic or low doses of antipsychotics. In this exploratory, double-blind study, the relationship between plasma prolactin concentration and central D2 receptor occupancy was examined in 13 schizophrenic patients treated with the experimental antipsychotic drug raclopride (2, 6, or 12 mg daily). D2 receptor occupancy was determined by positron emission tomography and was related to antipsychotic effect as measured by the Brief Psychiatric Rating Scale. Plasma prolactin concentration was increased in eight of nine patients with a D2 receptor occupancy greater than 50%, whereas it was normal among patients with a D2 receptor occupancy less than 50% (p < 0.01). Plasma prolactin concentration measured 4 hours after the morning dose of raclopride correlated significantly with plasma raclopride concentration (r = 0.92, p < 0.01), the degree of D2 receptor occupancy (r = 0.81,p < 0.01), and the antipsychotic effect (r = 0.79, p < 0.01). Further controlled studies that include low doses of antipsychotic drugs may warrant a reconciliation of plasma prolactin as a useful tool in clinical monitoring of antipsychotic drug treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690696     DOI: 10.1097/00004714-199808000-00010

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  18 in total

1.  Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

Authors:  Rajiv Tandon
Journal:  Psychiatr Q       Date:  2002

2.  Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: is it a predictive factor?

Authors:  Amresh Shrivastava; Megan Johnston; Yves Bureau; Nilesh Shah
Journal:  Innov Clin Neurosci       Date:  2012-04

Review 3.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

4.  Hyperprolactinemia associated with risperidone: a case report and review of literature.

Authors:  Ahmed Aboraya; Jennifer E Fullen; Barbara L Ponieman; Eugene H Makela; Melissa Latocha
Journal:  Psychiatry (Edgmont)       Date:  2004-11

Review 5.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.

Authors:  Hadine Joffe; Frances J Hayes
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

7.  The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.

Authors:  Eduardo R Butelman; Szymon Rus; Denise S Simpson; Angela Wolf; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2008-07-01       Impact factor: 4.030

8.  Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Pei Yan Zhang; Gui Ying Wu; Yu Cun Shen
Journal:  Psychopharmacology (Berl)       Date:  2004-07-31       Impact factor: 4.530

9.  Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.

Authors:  Rodrigo A Bressan; Kjell Erlandsson; Edgar P Spencer; Peter J Ell; Lyn S Pilowsky
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 10.  Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Authors:  O D Howes; A Egerton; V Allan; P McGuire; P Stokes; S Kapur
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.